CLN6 disease

CLN6 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms of this condition typically begin between early and late childhood, but sometimes they can appear in adulthood.

Most children with CLN6 disease initially experience the loss of previously acquired skills (developmental regression). Affected individuals can also develop recurrent seizures (epilepsy), difficulty coordinating movements (ataxia), muscle twitches (myoclonus), impaired speech (dysarthria), and vision loss. The movement problems worsen over time until affected children cannot walk, stand, or sit without assistance. Intellectual function also declines over time. Most children with CLN6 disease do not survive into adulthood.

Some people with CLN6 disease do not show signs or symptoms of the condition until adulthood, typically after age 30. These individuals can have epilepsy, ataxia, dysarthria, and a progressive loss of intellectual function. CLN6 disease usually does not cause vision loss in affected adults. Adults with this condition do not often survive more than 10 years after diagnosis.

CLN6 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation "CLN," meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.

Frequency

The incidence of CLN6 disease is unknown; more than 125 cases have been described in the scientific literature. Collectively, all forms of NCL affect an estimated 1 in 100,000 individuals worldwide.

Causes

Mutations in the CLN6 gene cause CLN6 disease. The CLN6 gene provides instructions for making a protein whose function is not well understood. Within cells, the CLN6 protein is found in a structure called the endoplasmic reticulum, which is involved in protein processing and transport. Research suggests that the CLN6 protein helps cells get rid of materials they no longer need.

Most CLN6 gene mutations result in the production of an abnormal CLN6 protein that is quickly broken down (degraded). As a result, there is a severe reduction in the amount of functional CLN6 protein in cells. While it is not known how the loss of this protein
causes the signs and symptoms of CLN6 disease, it is likely that the protein’s quick
degradation contributes to the childhood onset of CLN6 disease.

In the cases in which CLN6 disease develops in adulthood, CLN6 gene mutations
often result in a CLN6 protein with reduced function. Research suggests that these
CLN6 gene mutations allow enough functional protein to be produced so that signs and
symptoms of the disorder do not develop until later in life.

CLN6 disease, like other NCLs, is characterized by the accumulation of proteins
and other substances in lysosomes, which are cell structures that digest and recycle
different types of molecules. These accumulations occur in cells throughout the
body; however, nerve cells seem to be particularly vulnerable to their effects. The
accumulations can cause cell damage leading to cell death. The progressive death of
nerve cells in the brain and other tissues leads to the signs and symptoms of CLN6
disease. However, it is unclear how mutations in the CLN6 gene are involved in the
buildup of substances in lysosomes in CLN6 disease. These accumulations occur in
more cells throughout the body in children with CLN6 disease than in affected adults.

**Inheritance Pattern**

This condition is inherited in an autosomal recessive pattern, which means both copies
of the gene in each cell have mutations. The parents of an individual with an autosomal
recessive condition each carry one copy of the mutated gene, but they typically do not
show signs and symptoms of the condition.

**Other Names for This Condition**

- ceroid lipofuscinosis neuronal 6
- CLN6-related neuronal ceroid lipofuscinosisis
- neuronal ceroid lipofuscinosisis 6

**Diagnosis & Management**

**Genetic Testing Information**

- What is genetic testing? /primer/testing/genetictesting
- Genetic Testing Registry: Ceroid lipofuscinosis neuronal 6

**Research Studies from ClinicalTrials.gov**

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22CLN6+disease%22+OR+%22Neuronal+Ceroid-Lipofuscinoses%22
Other Diagnosis and Management Resources

- MedlinePlus Encyclopedia: Neuronal Ceroid Lipofuscinoses (NCL)
  https://medlineplus.gov/ency/article/001613.htm
- University of Rochester Batten Center
  https://www.urmc.rochester.edu/neurology/batten-disease-center.aspx

Additional Information & Resources

Health Information from MedlinePlus

- Encyclopedia: Neuronal Ceroid Lipofuscinoses (NCL)
  https://medlineplus.gov/ency/article/001613.htm
- Health Topic: Degenerative Nerve Diseases
  https://medlineplus.gov/degenerativenervediseases.html

Genetic and Rare Diseases Information Center

- Neuronal ceroid lipofuscinosis 6
  https://rarediseases.info.nih.gov/diseases/1224/neuronal-ceroid-lipofuscinosis-6

Additional NIH Resources

- National Institute of Neurological Disorders and Stroke: Batten Disease Fact Sheet
  https://www.ninds.nih.gov/Disorders/All-Disorders/Batten-Disease-Information-Page
- National Institute of Neurological Disorders and Stroke: Epilepsy Information Page
  https://www.ninds.nih.gov/Disorders/All-Disorders/Epilepsy-Information-Page

Educational Resources

- Baylor College of Medicine: Myoclonus
  https://www.bcm.edu/healthcare/care-centers/parkinsons/conditions/myoclonus
- MalaCards: neuronal ceroid lipofuscinosis
  https://www.malacards.org/card/neuronal_ceroid_lipofuscinosis_2
- Orphanet: Neuronal ceroid lipofuscinosis
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=216
- The University of Arizona Health Sciences
  https://disorders.eyes.arizona.edu/disorders/neuronal-ceroid-lipofuscinoses
- University College London: NCL Resource - A Gateway for Batten Disease
  https://www.ucl.ac.uk/ncl-disease/
Patient Support and Advocacy Resources

- American Association on Intellectual and Developmental Disabilities (AAIDD)  
  https://www.aaidd.org/
- Batten Disease Family Association  
  http://www.bdfa-uk.org.uk/variant-late-infantile-onset-ncl5-cln6-cln7-and-cln8-diseases-others/
- Batten Disease Support and Research Association  
  https://bdsra.org/
- Beyond Batten Disease Foundation  
  https://beyondbatten.org/
- Metabolic Support UK  
  https://www.metabolicsupportuk.org/

Scientific Articles on PubMed

- PubMed  
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Neuronal+Ceroid-Lipofuscinoses+\%5BMAJR%5D%29+AND+%28CLN6\%5BTIAB%5D%29+AND+english\%5Bl%5D+AND+human\%5Bmh\%5D+AND+%22last\+3600\+days\%22\%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- CEROID LIPOFUSCINOSIS, NEURONAL, 6  
  http://omim.org/entry/601780

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26115733  
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520821/
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21819394
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23402926
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27165443
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23602993
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631127/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22778232

Reprinted from Genetics Home Reference:
  https://ghr.nlm.nih.gov/condition/cln6-disease

Reviewed: January 2017
Published: March 3, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services